Novartis iptacopan met Phase II study primary endpoint in rare kidney disease

 Phase II primary endpoint results for investigational iptacopan in IgAN

      demonstrated effective and clinically meaningful reduction of 
      proteinuria1 -- a key risk predictor in kidney disease progression2 
 
   -- Iptacopan also showed a trend toward stabilization of kidney function1; 
      Phase III clinical trial APPLAUSE is underway 
 
   -- There are no currently approved treatments for IgAN -- a rare and often 
      progressive kidney disease that mainly affects young adults and can 
      progress to kidney failure3-7 
 
   -- Iptacopan is in development for several complement-driven renal diseases 
      (CDRDs), including IgAN and C3 glomerulopathy (C3G), and the blood 
      disorder paroxysmal nocturnal hemoglobinuria (PNH), targeting a key 
      driver of these diseases 

https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Press-Release-nbsp-Novartis-announces-iptacopan-met-Phase-II-study-primary-endpoint-in-rare-kidney-35531428/